Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
November 02 2021 - 4:05PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage,
precision oncology biopharmaceutical company, today announced that
the Company’s third quarter 2021 financial results will be released
on Tuesday, November 9, 2021. Company management will host a
conference call on Tuesday, November 9, 2021 at 2:00 p.m. Pacific
Time/ 5:00 p.m. Eastern Time to discuss the financial results and
other recent corporate highlights.
The press release and live audio webcast can be
accessed via the Investor section of the Company’s website at
www.calithera.com. The conference call can be accessed by dialing
(855) 783-2599 (domestic) or (631) 485-4877 (international) and
refer to conference ID 3797324. Please log in approximately 5-10
minutes before the event to ensure a timely connection. The
archived webcast will remain available for replay on Calithera’s
website for 30 days.
About CalitheraCalithera
Biosciences is a clinical-stage, precision oncology
biopharmaceutical company developing targeted therapies to redefine
treatment for biomarker-specific patient populations. Driven by a
commitment to rigorous science and a passion for improving the
lives of people impacted by cancer and other life-threatening
diseases, Calithera is advancing a robust pipeline of
investigational, small molecule oncology compounds with a
biomarker-driven approach that targets genetic vulnerabilities in
cancer cells to deliver new therapies for patients suffering from
aggressive hematologic and solid tumor cancers for which there are
currently limited treatment options.
Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please visit
www.calithera.com.
Forward Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"will," "expect," "anticipate," "estimate," "intend," "poised" and
similar expressions (as well as other words or expressions
referencing future events, conditions, or circumstances) are
intended to identify forward-looking statements. These statements
include those related to the safety, tolerability and efficacy of
Calithera’s product candidates, the overall advancement of
Calithera’s product candidates in clinical trials, the unmet need
in the treatment of patients with advanced disease, and Calithera’s
plans to continue development of its product candidates. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. The potential product candidates
that Calithera develops may not progress through clinical
development or receive required regulatory approvals within
expected timelines or at all. In addition, clinical trials may not
confirm any safety, potency or other product characteristics
described or assumed in this press release. Such product candidates
may not be beneficial to patients or be successfully
commercialized. The failure to meet expectations with respect to
any of the foregoing matters may have a negative effect on
Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's periodic filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements are not
guarantees of future performance and speak only as of the date
hereof, and, except as required by law, Calithera disclaims any
obligation to update these forward-looking statements to reflect
future events or circumstances.
CONTACTS:Stephanie Wong
ir@Calithera.com650-870-1063
INVESTORS:Burns McClellanLee
Roth212.213.0006lroth@burnsmc.com
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2023 to Aug 2024